Flawed ivermectin preprint highlights challenges of COVID drug studies.

@article{Reardon2021FlawedIP,
  title={Flawed ivermectin preprint highlights challenges of COVID drug studies.},
  author={Sara Reardon},
  journal={Nature},
  year={2021}
}

Ivermectin and the Integrity of Healthcare Evidence During COVID-19

Ivermectin will be used to explore the ethics of how healthcare evidence must be critically appraised, even, or especially, during a pandemic, and the core principles of critical appraisal will be described in the article, and how they can be adapted for different types of readers.

Ivermectin under scrutiny: a systematic review and meta-analysis of efficacy and possible sources of controversies in COVID-19 patients

Ivermectin did not have any significant effect on outcomes of COVID-19 patients and as WHO recommends, use of this drug should be limited to clinical trials.

Ivermectin role in COVID-19 treatment (IRICT): single-center, adaptive, randomized, double-blind, placebo-controlled, clinical trial

The study recommends against using either ivermectin or hydroxychloroquine for treatment of COVID-19 in hospitalized patients with any degree of severity.

Misinformation in the time of COVID: fighting the spread of fake news

The spread of misinformation has been part of the social landscape since pen was put to paper. Conspiracy theorists have existed since before the assassination of JKF in 1963, but in the twenty-first

Severe cutaneous adverse reactions associated with systemic ivermectin: A pharmacovigilance analysis

It is suggested that ivermectin is associated with SCARs on rare occasions and Dermatologists should be aware of this given the increase in iverMectin misuse.

Drug safety of frequently used drugs and substances for self-medication in COVID-19

During the COVID-19 pandemic, the behavior of self-medication has increased. The dissemination of misleading information regarding the efficacy of certain drugs or substances for the prevention and

COVID‐19 in Latin America and the Caribbean: Two years of the pandemic

Worldwide, nations have struggled during the coronavirus disease 2019 (COVID‐19) pandemic. However, Latin America and the Caribbean faced an unmatched catastrophic toll. As of March 2022, the region

COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?

Ivermectin: a mini-review

The use of ivermectin as a routine treatment or preventive measure for COVID-19 infection is not recommended at this time due to concern for adverse events, specifically neurotoxicity, as well as a paucity of supporting evidence.

References

SHOWING 1-4 OF 4 REFERENCES

Ivermectin for preventing and treating COVID‐19

To assess the efficacy and safety of ivermectin compared to no treatment, standard of care, placebo, or any other proven intervention for people with COVID-19 receiving treatment as inpatients or outpatients, and for prevention of an infection with SARS-CoV-2 (postexposure prophylaxis).

Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines

Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin, and the apparent safety and low cost suggest that iverMectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.

Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic

Early addition of Ivermectin to standard care is very effective drug for treatment of COVID-19 patients with significant reduction in mortality,rt-PCR conversion days, recovery time hospital stay compared to Hydroxychloroquine plus standard care.